Table 9.6f

Immunosuppression Use for Maintenance by Regimen

One Year Following Transplantation, 1996 to 2005

Recipients with Liver Transplants

  Transplant Year
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Transplants 4,083 4,188 4,516 4,751 4,995 5,191 5,331 5,673 6,169 6,441
Functioning Graft at 1 Year PostTx 3,006 3,182 3,483 3,658 3,899 4,094 4,307 4,584 5,020 5,124
With Maintenance Use Recorded at 1 Year PostTx 428 649 2,258 3,411 3,714 4,026 4,210 4,447 4,904 4,997
--- + MMF/MPA 0.0% 0.2% 0.1% 0.1% 0.0% 0.1% 0.2% 0.4% 0.3% 0.3%
--- + MMF/MPA + OtherAntimet 0.0% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.2% 0.4% 1.0% 1.1% 1.3% 2.4%
--- + MMF/MPA + Steroids 0.0% 0.5% 0.3% 0.4% 0.3% 0.3% 0.4% 0.4% 0.4% 0.4%
--- + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1%
--- + OtherAntimet + Steroids 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0%
--- + Siro/Evero 0.0% 0.0% 0.1% 0.2% 0.8% 1.0% 1.7% 1.5% 2.0% 2.0%
--- + Siro/Evero + Steroids 0.0% 0.0% 0.1% 0.1% 0.3% 1.0% 0.9% 0.8% 1.6% 1.4%
--- + Steroids 0.9% 0.5% 1.8% 1.8% 1.6% 0.6% 0.8% 0.5% 0.4% 0.4%
CyA 1.2% 1.1% 3.6% 4.2% 3.1% 2.5% 2.5% 1.9% 1.9% 1.7%
CyA + MMF/MPA 0.7% 0.6% 2.3% 1.6% 1.3% 1.4% 1.6% 1.9% 2.4% 2.9%
CyA + MMF/MPA + OtherAntimet 0.0% 0.5% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1%
CyA + MMF/MPA + Steroids 4.4% 4.8% 4.4% 5.0% 4.0% 3.2% 2.0% 2.1% 2.0% 1.7%
CyA + OtherAntimet 0.2% 0.2% 0.2% 0.2% 0.1% 0.1% 0.0% 0.1% 0.2% 0.0%
CyA + OtherAntimet + Steroids 10.3% 6.6% 2.4% 2.5% 1.7% 0.8% 0.3% 0.2% 0.3% 0.1%
CyA + Siro/Evero 0.0% 0.0% 0.3% 0.1% 0.9% 0.5% 0.3% 0.4% 0.3% 0.5%
CyA + Siro/Evero + Steroids 0.0% 0.0% 0.3% 0.3% 0.3% 0.4% 0.3% 0.3% 0.1% 0.1%
CyA + Steroids 15.7% 9.7% 11.1% 10.2% 5.7% 2.9% 2.3% 2.0% 1.7% 1.2%
Tac 8.6% 17.3% 19.4% 20.6% 23.6% 28.9% 31.3% 30.1% 28.3% 28.6%
Tac + MMF/MPA 1.2% 1.8% 4.8% 5.5% 7.1% 7.4% 10.1% 13.7% 15.2% 18.1%
Tac + MMF/MPA + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.2% 0.1% 0.2% 0.3% 0.2% 0.2%
Tac + MMF/MPA + Steroids 7.9% 9.6% 8.8% 10.3% 10.8% 13.2% 12.6% 14.1% 15.6% 16.8%
Tac + OtherAntimet 0.0% 0.5% 0.6% 0.3% 0.5% 0.2% 0.5% 0.3% 0.6% 0.1%
Tac + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + OtherAntimet + Steroids 6.1% 3.4% 2.9% 1.4% 1.1% 1.4% 1.4% 1.0% 0.5% 0.3%
Tac + Siro/Evero 0.0% 0.2% 0.0% 0.4% 2.4% 2.5% 2.3% 2.4% 2.9% 2.1%
Tac + Siro/Evero + Steroids 0.0% 0.0% 0.1% 0.6% 3.0% 2.3% 2.1% 1.5% 1.5% 1.2%
Tac + Steroids 35.5% 31.4% 32.9% 30.5% 26.8% 22.7% 22.3% 20.9% 18.1% 15.8%
Other Regimen 7.0% 11.2% 3.2% 3.6% 4.3% 5.8% 2.7% 2.2% 1.8% 1.6%


Source: OPTN/SRTR Data as of May 1, 2007.

Percentages are calculated based on the total number of patients with maintenance use at one year following transplantation. They sum to 100 percent for each column.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.